Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CCR5 | P51681 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.34 |
| ▸ | NOS3 | P29474 | 2/20 | 0.33 |
| ▸ | NOS2 | P35228 | 2/20 | 0.33 |
| ▸ | CCR8 | P51685 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | TERT | O14746 | 1/20 | 0.32 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | METAP2 | P50579 | 1/20 | 0.30 |
| ▸ | S100A4 | P26447 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | CASP6 | P55212 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22808709 | 0.82 | CCR1 (0.42) | CCR1RAB9ACCR5CYP1A2NOS3 | |
| SCHEMBL6776759 | 0.78 | NOS3 (0.39) | CCR1RAB9ACCR5CYP1A2NOS3 | |
| SCHEMBL15426482 | 0.76 | RAB9A (0.37) | CCR1RAB9ACCR5CYP1A2NOS3 | |
| SCHEMBL18878176 | 0.76 | CCR1 (0.37) | CCR1RAB9ACCR5CYP1A2NOS3 | |
| SCHEMBL26712602 | 0.76 | CHRNB2 (0.33) | RAB9AKDM4EALDH1A1METAP2 | |
| SCHEMBL25153150 | 0.76 | APP (0.40) | CCR1RAB9ACCR5CYP1A2NOS3 | |
| SCHEMBL27046101 | 0.76 | APP (0.32) | NOS3NOS2APPMETAP2 | |
| SCHEMBL17052908 | 0.76 | APP (0.34) | APP | |
| SCHEMBL7222434 | 0.76 | NOS2 (0.54) | RAB9ANOS3NOS2ADORA2AADORA1 | |
| SCHEMBL16923586 | 0.76 | KDM4E (0.38) | CCR1RAB9ACCR5CYP1A2APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118005640-A | GCN2 inhibitors and uses thereof | 默克专利股份有限公司 | 2024-05-10 | — | — | CN | disclosed |
| CN-111918651-B | GCN2 inhibitors and uses thereof | 默克专利股份有限公司 | 2024-01-30 | — | — | CN | disclosed |
| US-20230348439-A1 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES INC (US) | 2023-11-02 | — | — | US | disclosed |
| CN-111918651-A | GCN2 inhibitors and uses thereof | 默克专利股份有限公司 | 2020-11-10 | — | — | CN | disclosed |
| WO-2017136870-A9 | HALOALLYLAMINE INDOLE AND AZAINDOLE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | PHARMAXIS LTD. (AU) | 2018-02-15 | — | — | WO | disclosed |
| WO-2017136870-A1 | HALOALLYLAMINE INDOLE AND AZAINDOLE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | PHARMAXIS LTD. (AU) | 2017-08-17 | — | — | WO | disclosed |
| WO-2017133657-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATMENT, AMELIORATION OR PREVENTION OF INFLUENZA | SAVIRA PHARMACEUTICALS GMBH (AT) | 2017-08-10 | — | — | WO | disclosed |
| US-9701689-B2 | Substituted pyridines and pyridazines as CCR10 receptor inhibitors | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2017-07-11 | — | — | US | disclosed |
| US-20150299214-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2015-10-22 | — | — | US | disclosed |
| EP-1944305-B1 | Quinoline derivatives as phosphodiesterase inhibitors | GLAXO GROUP LTD (GB) | 2011-10-19 | — | — | EP | disclosed |
| US-7572915-B2 | 4-[(3-methylphenyl)amino]-6-(methylsulfonyl)-3-quinolinecarboxamide; asthma, COPD, allergic rhinitis, or rheumatoid arthritis in a human | GLAXO GROUP LIMITED (GB) | 2009-08-11 | — | — | US | disclosed |
| US-7566786-B2 | Quinoline derivatives as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2009-07-28 | — | — | US | disclosed |
| US-7566786-B2 | Quinoline derivatives as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2009-07-28 | — | — | US | disclosed |
| EP-1944305-A1 | Quinoline derivatives as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2008-07-16 | — | — | EP | disclosed |
| EP-1633748-B1 | QUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LTD (GB) | 2008-03-05 | — | — | EP | disclosed |
| US-20070142373-A1 | Quinoline derivatives as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-06-21 | — | — | US | disclosed |
| US-20070142373-A1 | Quinoline derivatives as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-06-21 | — | — | US | disclosed |
| US-20070049570-A1 | Quinoline derivatives as phosphodiesterase inhibitors | DEAN ANTHONY W | 2007-03-01 | — | — | US | disclosed |
| US-20070049570-A1 | Quinoline derivatives as phosphodiesterase inhibitors | DEAN ANTHONY W | 2007-03-01 | — | — | US | disclosed |
| WO-2004103998-A1 | QUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299214-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | ARG1, H1-0, TYR | CCR1 84/4885RAB9A 2144/4885CCR5 825/4885 |
| US-20230348439-A1 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AR, FSHR, NR5A1 | CCR1 3785/4885RAB9A 2639/4885CCR5 1379/4885 |
| US-20070049570-A1 | Quinoline derivatives as phosphodiesterase inhibitors | PDE3B, PDE4B, PDE4A | CCR1 2705/4885RAB9A 211/4885CCR5 606/4885 |
| US-20070142373-A1 | Quinoline derivatives as phosphodiesterase inhibitors | PDE3B, PDE4B, PDE4A | CCR1 2705/4885RAB9A 211/4885CCR5 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.